MGF (Mechano Growth Factor) Research Guide Ireland

Overview

Mechano Growth Factor (MGF) is the name given to a splice variant of the insulin-like growth factor 1 (IGF-1) gene, formally designated IGF-1Ec in humans (the rodent equivalent is often referred to as IGF-1Eb). Unlike the liver-derived systemic IGF-1Ea isoform that circulates in blood, MGF is produced locally within skeletal muscle tissue in response to mechanical loading, damage, or stretch, which is the origin of its common name. Foundational research identifying and characterising this splice variant was carried out by Geoffrey Goldspink and colleagues at University College London, whose work described how mechanical stimulation of muscle triggers alternative splicing of the IGF-1 gene to produce a locally-acting peptide implicated in activating satellite cells — the muscle-resident stem cells responsible for muscle repair, remodelling, and hypertrophy. This guide is for educational and research purposes only. Not medical advice.

Clinical & Research Status

Evidence Type	Status
Human RCT	✗
Observational	✔
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

Mechanism of Action

MGF is produced through alternative splicing of the IGF-1 gene's exon structure, generating a peptide with a distinct C-terminal E-domain (the "Ec peptide") not present in the mature, circulating IGF-1Ea isoform. Research by Goldspink G and colleagues proposed that mechanical overload, stretch, or damage to skeletal muscle fibres upregulates this splice variant locally, where it is theorised to act on satellite cells — quiescent myogenic stem cells that reside beneath the basal lamina of muscle fibres. Preclinical work has investigated whether MGF, or its synthetic C-terminal E-domain peptide fragment, promotes satellite cell activation, proliferation, and progression toward differentiation, distinguishing its proposed local, transient signalling role from the more sustained, differentiation-promoting role attributed to mature IGF-1Ea. Some in vitro and rodent studies have further explored MGF's proposed activity through IGF-1 receptor-related and receptor-independent pathways, though the precise receptor pharmacology of the E-domain peptide fragment used in most synthetic peptide research remains incompletely characterised in the published literature.

Research Areas & Reported Effects

Satellite Cell Activation

The principal research interest in MGF concerns its proposed role in activating dormant satellite cells following mechanical loading or muscle injury, a necessary early step in muscle regeneration and hypertrophic adaptation. Goldspink's group and subsequent researchers examined MGF mRNA expression patterns following resistance exercise and eccentric-contraction-induced muscle damage in animal and some human muscle biopsy studies.

Muscle Damage and Repair Response

Research has tracked MGF splice variant expression in skeletal muscle following exercise-induced damage, examining the timing and magnitude of its upregulation relative to the classical liver-type IGF-1Ea isoform, which tends to rise later in the repair process, supporting a model of sequential local-then-systemic IGF-1 signalling in muscle recovery.

Ageing and Sarcopenia Models

Because satellite cell number and activation capacity decline with age, some research has examined whether MGF expression or signalling is blunted in aged muscle compared with younger tissue, and whether this contributes to age-related muscle loss (sarcopenia) and reduced regenerative capacity.

Cardiac and Neuroprotective Preclinical Models

A smaller body of preclinical research has explored MGF E-domain peptide effects outside skeletal muscle, including rodent models of cardiac tissue protection following ischaemic injury and some neuronal survival models, extending the proposed local-repair-signalling concept beyond muscle tissue.

Research Data Summary

Study / Model	Reported Effect
Rabbit Muscle Stretch Model (Goldspink G et al.)	Identified and characterised the IGF-1 splice variant upregulated specifically by mechanical overload, distinguishing it from liver-type IGF-1Ea expression.
Human Muscle Biopsy, Resistance Exercise Studies	Reported detectable increases in MGF (IGF-1Ec) mRNA expression following acute resistance exercise, with a different time course than IGF-1Ea.
In Vitro Satellite Cell / Myoblast Culture Studies	Reported synthetic MGF E-domain peptide fragments promoted proliferation markers in cultured myoblasts in some published assays.
Aged Rodent Muscle Models	Reported reduced or delayed MGF expression response to mechanical loading in aged versus young animals, associated with reduced regenerative capacity.

Stack Combinations Studied

• MGF + IGF-1 (Ea, systemic isoform) → Research rationale: Investigated as a sequential signalling model in muscle repair research, where MGF is proposed to drive early satellite cell activation while IGF-1Ea supports later-stage differentiation and protein synthesis.
• MGF + resistance exercise/mechanical loading protocols (animal and human study designs) → Research rationale: Nearly all MGF expression research uses a mechanical loading or damage stimulus as the experimental trigger, since MGF splicing is itself defined by its induction through mechanical stress rather than by exogenous administration alone.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
In Vitro Myoblast/Satellite Cell Assay Protocol	Nanomolar range synthetic E-domain peptide concentrations reported in published assays	24-72 hours culture exposure	Single or repeated media addition per assay design	Satellite cell proliferation and myoblast activity marker assays.
Rodent Mechanical Overload Model Protocol	Not applicable — MGF expression induced endogenously via loading, not typically injected in most foundational studies	Days following loading stimulus	Single loading event, tissue sampled at multiple timepoints	Time-course characterisation of MGF versus IGF-1Ea expression following muscle overload or damage.

Observed Side Effects in Research

• No consistent adverse effects reported in the limited published in vitro or endogenous expression literature
• No completed human RCT safety data exists for exogenous synthetic MGF peptide administration
• Theoretical concerns exist in commentary literature regarding unregulated cell proliferation signalling associated with IGF-1 pathway peptides generally, though this has not been directly demonstrated for MGF in controlled human research

The MGF research base consists primarily of gene expression studies following natural mechanical loading, plus a smaller number of in vitro assays using synthetic E-domain peptide fragments. There is no published, peer-reviewed human clinical trial data evaluating the safety or efficacy of injected synthetic MGF peptide, and most commercially available "MGF" research peptides have not been validated against the specific splice-variant biology described in the original academic literature.

Compound Data

CAS Number

Not formally assigned for the synthetic 24-amino-acid C-terminal E-domain research fragment; parent IGF-1 gene product, not a single registered small-molecule CAS entity

Molecular Formula

Variable — depends on which E-domain peptide fragment is synthesised; full-length MGF/IGF-1Ec splice variant is a larger propeptide, not typically synthesised in full

Molecular Weight

Approximately 2.9-3.0 kDa for the commonly referenced 24-residue synthetic E-domain fragment used in research

Half-Life

Very short (minutes) for the synthetic peptide fragment in circulation; endogenous MGF is understood to act locally within muscle tissue rather than systemically

Synonyms

IGF-1Ec (human), IGF-1Eb (rodent), Mechano Growth Factor, IGF-1 E-domain peptide

Research Classification

IGF-1 gene splice variant, Locally-acting muscle repair signalling peptide

Scientific References

• [Yang SY, Goldspink G 2002] — Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. — FEBS Letters — [In vitro / Animal]
• [Goldspink G 2005] — Mechanical signals, IGF-I gene splicing, and muscle adaptation. — Physiology (American Physiological Society) — [Review / Mechanistic]
• [Hameed M et al. 2003] — Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. — Journal of Physiology — [Human Observational]
• [Owino V et al. 2001] — Age-related loss of skeletal muscle function and the inability to express the autocrine form of insulin-like growth factor-1 (MGF) in response to mechanical overload. — FEBS Letters — [Animal]
• [Stavropoulou A et al. 2009] — IGF-1 expression in infarcted myocardium and MGF E-peptide actions in cardiac cell survival models. — Preclinical / Basic Research literature — [Animal / In vitro]

Note on the research base: The academic literature on MGF concerns primarily the naturally occurring IGF-1 splice variant and its endogenous expression pattern, characterised mainly through gene expression (mRNA) studies. Research using synthetic E-domain peptide fragments is a smaller, more preliminary in vitro and animal literature, and has not progressed to human clinical trials at the time of writing.

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*